Nanostics is focused on development and commercialization of novel, non-invasive diagnostic tests for cancer to help better manage disease. The core technology is in development will be able to diagnose disease from a single drop of blood by combining a highly sensitive extracellular vesicle detection platform with advanced machine learning algorithms. Their lead product, ClarityDx, is the most accurate diagnostic test to diagnose aggressive prostate cancer, and is positioned to emerge as the world’s leading diagnostic tool for prostate cancer.
Edmonton, Alberta
